Joel Schlessinger MD - Hydroquinone Update / Strategies
-
Upload
joel-schlessinger -
Category
Health & Medicine
-
view
1.152 -
download
1
description
Transcript of Joel Schlessinger MD - Hydroquinone Update / Strategies
![Page 1: Joel Schlessinger MD - Hydroquinone Update / Strategies](https://reader035.fdocuments.in/reader035/viewer/2022081404/559597631a28abbd1e8b477b/html5/thumbnails/1.jpg)
Hydroquinone Update/StrategiesJoel Schlessinger MD
Course Director, Cosmetic Surgery Forum
![Page 2: Joel Schlessinger MD - Hydroquinone Update / Strategies](https://reader035.fdocuments.in/reader035/viewer/2022081404/559597631a28abbd1e8b477b/html5/thumbnails/2.jpg)
Disclosure of Relevant Relationships with IndustryJoel Schlessinger, MD
Advisory Board / Consultant
Abbott Pharma., Allergan, Amgen, Artes, Dermik, Galderma, Genentech, Glaxo, Health and Wellness Council of America, Kythera, MEDICIS, Mentor, Merz, MJD Communications, Novartis, Obagi, Ortho Pharma. (Johnson & Johnson), Stiefel, TheDerm.org
Researcher
3M Pharma., Abbot Pharma., Allergan, Amgen, Astellas, Barrier Therapeutics, Biogen, Centocor, Clay-Park Labs, Collagenix, Connetics, Dermik, Dow, ESC Medical, Fujisawa, Galderma, Genentech, Glaxo Pharma., GlenmarkPharma., HealthPoint, Immunex, Ipsen / Inamed, Kythera, MEDICIS, Mentor, Merz, Novartis, Novum, NUCRYST, Ortho Pharma. (Johnson & Johnson), PenedermPharma., Perrigo, Pfizer, QLT USA, Regeneratio PharmaAG, Sandoz, Schering Plough, StiefelLabs, UBC/Vitae
Stockholder
Allergan, Excel Cosmeceuticals, MEDICIS, J and J, Obagi
![Page 3: Joel Schlessinger MD - Hydroquinone Update / Strategies](https://reader035.fdocuments.in/reader035/viewer/2022081404/559597631a28abbd1e8b477b/html5/thumbnails/3.jpg)
Proposed Rule
• Skin Bleaching Drug Products for OTC Use
• August 29, 2006
• No decision yet
• Could affect over 200 products in use
![Page 4: Joel Schlessinger MD - Hydroquinone Update / Strategies](https://reader035.fdocuments.in/reader035/viewer/2022081404/559597631a28abbd1e8b477b/html5/thumbnails/4.jpg)
Current
• OTC 1.5% to 2% have GRASE (generally recognized as safe and effective)
• Majority of OTC and Rx HQs have 2% to 4%
• New rule would extend DESI, a 1962 rule, (Drug Efficacy Study Implementation) to those currently exempted from an NDA
![Page 5: Joel Schlessinger MD - Hydroquinone Update / Strategies](https://reader035.fdocuments.in/reader035/viewer/2022081404/559597631a28abbd1e8b477b/html5/thumbnails/5.jpg)
Quote from Dr. Kligman
“If we give up on hydroquinone, we’re damn fools!”
![Page 6: Joel Schlessinger MD - Hydroquinone Update / Strategies](https://reader035.fdocuments.in/reader035/viewer/2022081404/559597631a28abbd1e8b477b/html5/thumbnails/6.jpg)
New Rule
• FDA intends to consider all HQs, whether Rx or OTC, as new drugs!
• Could it extend even to TriLuma?
![Page 7: Joel Schlessinger MD - Hydroquinone Update / Strategies](https://reader035.fdocuments.in/reader035/viewer/2022081404/559597631a28abbd1e8b477b/html5/thumbnails/7.jpg)
Evidence
• Some evidence of carcinogenicity in rats and mice in 1989 and 1992 following gavage (not dermal) administration
• HQ is highly absorbed (57%) in humans
• ? Ochronosis reports
![Page 8: Joel Schlessinger MD - Hydroquinone Update / Strategies](https://reader035.fdocuments.in/reader035/viewer/2022081404/559597631a28abbd1e8b477b/html5/thumbnails/8.jpg)
Do the studies add up?
• 100 mg/kg/day HQ to mice via oral gavage
• 50 mg/kg/day HQ to rats via oral gavage
• No toxicity when administered via dermal route in animals
• 5% HQ for 13 weeks in rats only showed irritation
![Page 9: Joel Schlessinger MD - Hydroquinone Update / Strategies](https://reader035.fdocuments.in/reader035/viewer/2022081404/559597631a28abbd1e8b477b/html5/thumbnails/9.jpg)
Absorption
• Absorption is highly species characteristic
• Metabolism is hepatic in humans and results in deactivation and detoxification in humans vs rats
• Rats tend to activate HQ
• Exposure route matters (oral vs dermal)
![Page 10: Joel Schlessinger MD - Hydroquinone Update / Strategies](https://reader035.fdocuments.in/reader035/viewer/2022081404/559597631a28abbd1e8b477b/html5/thumbnails/10.jpg)
Ochronosis
• Unclear why it is so high in reports, but not evidenced in US
• Dermchat experience (no reports of ochronosis over 1400 members
• No reports of ochronosis in chemical factory workers or other issues
• Kligman: Concerns of ochronosis and cancer come from “bureaucrats who have no background.”
![Page 11: Joel Schlessinger MD - Hydroquinone Update / Strategies](https://reader035.fdocuments.in/reader035/viewer/2022081404/559597631a28abbd1e8b477b/html5/thumbnails/11.jpg)
What else is there?
• Lumixyl: Oligopeptide that inhibits mushroom tyrosinase and human tyrosinase
• 43% reduction in melanin activity
• Non-toxic to melanocytes
• Can be used as an alternative to HQ
![Page 12: Joel Schlessinger MD - Hydroquinone Update / Strategies](https://reader035.fdocuments.in/reader035/viewer/2022081404/559597631a28abbd1e8b477b/html5/thumbnails/12.jpg)
Obagi system and other HQ compounds
• Obagi with Botox study
• Obagi along with Botox had significant improvement in results than Botox with Cetaphil
• 100% of patients wished to continue on Obagi vs20% in the Cetaphil group
![Page 13: Joel Schlessinger MD - Hydroquinone Update / Strategies](https://reader035.fdocuments.in/reader035/viewer/2022081404/559597631a28abbd1e8b477b/html5/thumbnails/13.jpg)
Figure 1. Hyperpigmentation.
0
1
2
3
4
0 30 60 90 120
Hydroquinone system + tretinoin
Standard skin care
None
Trace
Mild
Moderate
Severe
* P≤.05, ** P≤.01, *** P≤.001 compared with standard skin care
Mean
hyperpigmentation
score
Day
** *******
![Page 14: Joel Schlessinger MD - Hydroquinone Update / Strategies](https://reader035.fdocuments.in/reader035/viewer/2022081404/559597631a28abbd1e8b477b/html5/thumbnails/14.jpg)
Figure 2. Fine lines and wrinkles.
0
1
2
3
4
0 30 60 90 120
Hydroquinone system + tretinoin
Standard skin care
None
Trace
Mild
Moderate
Severe
* P≤.05, ** P≤.01 compared with standard skin care
Mean
fine lines/
wrinkles
score
Day
** **
![Page 15: Joel Schlessinger MD - Hydroquinone Update / Strategies](https://reader035.fdocuments.in/reader035/viewer/2022081404/559597631a28abbd1e8b477b/html5/thumbnails/15.jpg)
Figure 3. Patient satisfaction with overall improvement in facial appearance.
0
20
40
60
80
100
0 30 60 90 120 0 30 60 90 120
Satisfied
Extremely satisfied
Day
Standard skin care
Patients
(%)
20%
82%
89% 88% 89%
11% 12%
22%
55%
12%
[Significant between-group difference in overall ratings at days 30, 60, 90, and 120, P≤.001]
Hydroquinone system
+ tretinoin
![Page 16: Joel Schlessinger MD - Hydroquinone Update / Strategies](https://reader035.fdocuments.in/reader035/viewer/2022081404/559597631a28abbd1e8b477b/html5/thumbnails/16.jpg)
0
20
40
60
80
100
30 60 90 120 30 60 90 120
Somewhat improved
Improved
Greatly improved
Figure 4. Effect of study treatment in further enhancing facial appearance
after botulinum toxin type A treatment (a comparison with the effect of past
treatment using botulinum toxin type A alone).
Patients
(%)
Day
71%79%
92%86%
12% 7%
Standard skin care
11% 8%
[Significant between-group difference in overall ratings at all timepoints, P≤.001]
Hydroquinone system
+ tretinoin
![Page 17: Joel Schlessinger MD - Hydroquinone Update / Strategies](https://reader035.fdocuments.in/reader035/viewer/2022081404/559597631a28abbd1e8b477b/html5/thumbnails/17.jpg)
30%
10%
60%
Baseline
Day 120
Hydroquinone system
+ tretinoin
Standard skin care
64%
36%
69%
23%
65%
29%
7% Look younger/much younger
Look current age
Look older/much older
8%
Figure 5. Patient evaluation of facial appearance compared to age.
[Significant between-group difference in overall ratings at days 60, 90, and 120, P≤.05]
![Page 18: Joel Schlessinger MD - Hydroquinone Update / Strategies](https://reader035.fdocuments.in/reader035/viewer/2022081404/559597631a28abbd1e8b477b/html5/thumbnails/18.jpg)
Figure 6. Burning.
0
1
2
3
4
0 30 60 90 120
Hydroquinone system + tretinoin
Standard skin care
None
Trace
Mild
Moderate
Severe
* P≤.05, *** P≤.001 compared with standard skin care
Mean
burning
score
Day
*
***
*
![Page 19: Joel Schlessinger MD - Hydroquinone Update / Strategies](https://reader035.fdocuments.in/reader035/viewer/2022081404/559597631a28abbd1e8b477b/html5/thumbnails/19.jpg)
Figure 7. Dryness.
0
1
2
3
4
0 30 60 90 120
Hydroquinone system + tretinoin
Standard skin care
None
Trace
Mild
Moderate
Severe
** P≤.01, *** P≤.001 compared with standard skin care
Mean
dryness
score
Day
**
***
**
**
![Page 20: Joel Schlessinger MD - Hydroquinone Update / Strategies](https://reader035.fdocuments.in/reader035/viewer/2022081404/559597631a28abbd1e8b477b/html5/thumbnails/20.jpg)
Figure 8. Peeling.
0
1
2
3
4
0 30 60 90 120
Hydroquinone system + tretinoin
Standard skin care
None
Trace
Mild
Moderate
Severe
*** P≤.001 compared with standard skin care
Mean
peeling
score****** *** ***
Day
![Page 21: Joel Schlessinger MD - Hydroquinone Update / Strategies](https://reader035.fdocuments.in/reader035/viewer/2022081404/559597631a28abbd1e8b477b/html5/thumbnails/21.jpg)
Figure 9. Erythema.
0
1
2
3
4
0 30 60 90 120
Hydroquinone system + tretinoin
Standard skin care
None
Trace
Mild
Moderate
Severe
* P≤.05, *** P≤.001 compared with standard skin care
Mean
erythema
score
Day
**** ***
![Page 22: Joel Schlessinger MD - Hydroquinone Update / Strategies](https://reader035.fdocuments.in/reader035/viewer/2022081404/559597631a28abbd1e8b477b/html5/thumbnails/22.jpg)
Before and After
![Page 23: Joel Schlessinger MD - Hydroquinone Update / Strategies](https://reader035.fdocuments.in/reader035/viewer/2022081404/559597631a28abbd1e8b477b/html5/thumbnails/23.jpg)
Before and After
![Page 24: Joel Schlessinger MD - Hydroquinone Update / Strategies](https://reader035.fdocuments.in/reader035/viewer/2022081404/559597631a28abbd1e8b477b/html5/thumbnails/24.jpg)
Before and After
![Page 25: Joel Schlessinger MD - Hydroquinone Update / Strategies](https://reader035.fdocuments.in/reader035/viewer/2022081404/559597631a28abbd1e8b477b/html5/thumbnails/25.jpg)
Before and After